Tech Company Financing Transactions

Aureon Biosciences Funding Round

Aureon Biosciences, based in Yonkers, secured $3.8 million from private investors.

Transaction Overview

Company Name
Announced On
9/30/2011
Transaction Type
Debt
Amount
$3,838,665
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing-amended.

Company Information

Company Status
Out of Business
Industry
Medical Devices & Instruments
Mailing Address
28 Wells Ave.
Yonkers, NY 10701
USA
Email Address
Overview
Aureon Biosciences is a life science company founded in 2002, dedicated to enabling the advancement of predictive and personalized cancer treatment options.
Profile
Aureon Biosciences LinkedIn Company Profile
Social Media
Aureon Biosciences Company Twitter Account
Company News
Aureon Biosciences News
Facebook
Aureon Biosciences on Facebook
YouTube
Aureon Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Robert Shovlin
  Robert Shovlin LinkedIn Profile  Robert Shovlin Twitter Account  Robert Shovlin News  Robert Shovlin on Facebook
Chief Financial Officer
Robert Nostrand
  Robert Nostrand LinkedIn Profile  Robert Nostrand Twitter Account  Robert Nostrand News  Robert Nostrand on Facebook
Chief Scientific Officer
Michael Donovan
  Michael Donovan LinkedIn Profile  Michael Donovan Twitter Account  Michael Donovan News  Michael Donovan on Facebook
VP - Finance
Michael Facendola
  Michael Facendola LinkedIn Profile  Michael Facendola Twitter Account  Michael Facendola News  Michael Facendola on Facebook
VP - Marketing
Jason Alter
  Jason Alter LinkedIn Profile  Jason Alter Twitter Account  Jason Alter News  Jason Alter on Facebook
VP - Operations
Charles DiComo
  Charles DiComo LinkedIn Profile  Charles DiComo Twitter Account  Charles DiComo News  Charles DiComo on Facebook
VP - Sales
David Brown
  David Brown LinkedIn Profile  David Brown Twitter Account  David Brown News  David Brown on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/30/2011: Selexagen Therapeutics venture capital transaction
Next: 9/30/2011: BDNA venture capital transaction

 

Share this article

 


Where The Data Comes From

Our team works diligently to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary